{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:11:29Z","timestamp":1790683889923,"version":"4.1.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Physical liver injury is an acute and potentially serious adverse event that may result in acute liver failure or even death. Diagnosis is often challenging. Minocycline, a semi-synthetic second-generation tetracycline, has high fat solubility and good tissue permeability. It is widely used for acne treatment. This report presents a 32-year-old female hepatitis B carrier who took minocycline (50\u00a0mg twice daily) for acne. After 1\u00a0week, she experienced fatigue, jaundice, abdominal bloating, and discomfort. Upon admission, laboratory tests revealed significantly elevated transaminase levels, ascites on abdominal ultrasonography, positive hepatitis B markers, impaired coagulation function, and a final diagnosis of subacute liver failure with chronic hepatitis B. Following discontinuation of minocycline and initiation of liver enzyme protection therapy, the patient\u2019s liver and coagulation functions improved after undergoing artificial liver therapy combined with CRRT. This case highlights a rare occurrence of minocycline-induced liver injury in a hepatitis B carrier, emphasizing that acute liver injury is a potential and serious adverse effect of minocycline, particularly in patients with pre-existing liver disease.<\/jats:p>","DOI":"10.3389\/fphar.2024.1516217","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T06:23:55Z","timestamp":1734589435000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Severe liver injury induced by minocycline in hepatitis B patient: a Case Report"],"prefix":"10.3389","volume":"15","author":[{"given":"Ran","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"B1","author":"Anonymous Author","year":"2012","journal-title":"LiverTox: clinical and research information on drug induced liver injury"},{"key":"B2","doi-asserted-by":"publisher","first-page":"688780","DOI":"10.3389\/fphys.2021.688780","article-title":"Gut microbiota and chemical induced acute liver injury","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Physiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10096-017-3081-x","article-title":"Similarities and differences between doxycycline and minocycline: clinical and antimicrobial stewardship considerations","volume":"37","author":"Cunha","year":"2018","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2174\/1574886316666210120090446","article-title":"Adverse reactions induced by minocycline: a review of literature","volume":"16","author":"Dominic","year":"2021","journal-title":"Curr. Drug Saf."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL clinical practice guidelines: drug-induced liver injury","volume":"70","year":"2019","journal-title":"J. Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1007\/s00204-020-02885-1","article-title":"Drug induced liver injury: an update","volume":"94","author":"Garcia-Cortes","year":"2020","journal-title":"Arch. Toxicol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.phrs.2010.12.011","article-title":"The intestinal anti-inflammatory effect of minocycline in experimental colitis involves both its immunomodulatory and antimicrobial properties","volume":"63","author":"Garrido-Mesa","year":"2011","journal-title":"Pharmacol. Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.phrs.2012.10.006","article-title":"What is behind the non-antibiotic properties of minocycline?","volume":"67","author":"Garrido-Mesa","year":"2013","journal-title":"Pharmacol. Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3390\/pharmacy7030104","article-title":"Tetracycline allergy","volume":"7","author":"Hamilton","year":"2019","journal-title":"Pharm. (Basel)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1056\/NEJMra1816149","article-title":"Drug-induced liver injury: types and phenotypes","volume":"381","author":"Hoofnagle","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1111\/liv.15262","article-title":"Incidence and risk factors of drug-induced liver injury","volume":"42","author":"Li","year":"2022","journal-title":"Liver Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3390\/antibiotics10070757","article-title":"A review of systemic minocycline side effects and topical minocycline as a safer alternative for treating acne and rosacea","volume":"10","author":"Martins","year":"2021","journal-title":"Antibiotic"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol. Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/hep.28353","article-title":"Can rechallenge be done safely after mild or moderate drug-induced liver injury?","volume":"63","author":"Senior","year":"2016","journal-title":"Hepatology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"761167","DOI":"10.3389\/fphar.2021.761167","article-title":"Real-world data of tigecycline-associated drug-induced liver injury among patients in China: a 3-year retrospective study as assessed by the updated RUCAM","volume":"12","author":"Shi","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.12701\/yujm.2019.00297","article-title":"Drug-induced liver injury","volume":"37","author":"Suh","year":"2020","journal-title":"Yeungnam Univ. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/hep4.1088","article-title":"Drug-induced cholestasis","volume":"1","author":"Sundaram","year":"2017","journal-title":"Hepatol. Commun."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1086\/651277","article-title":"Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4(+) T cells","volume":"201","author":"Szeto","year":"2010","journal-title":"J. Infect. Dis."},{"key":"B19","first-page":"2801","article-title":"Literature analysis of DRESS syndrome caused by tetracyclines","volume":"21","author":"Wang","year":"2023","journal-title":"Cent. South Pharm."},{"key":"B20","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s11096-022-01397-5","article-title":"A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on Food and Drug Administration adverse event reporting system data","volume":"44","author":"Wei","year":"2022","journal-title":"Int. J. Clin. Pharm."},{"key":"B21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ijid.2022.04.024","article-title":"Prevalence and risk factors of tigecycline-induced liver injury: a multicenter retrospective study","volume":"120","author":"Yu","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"B22","first-page":"6","article-title":"The injury effect of tetracycline on human liver L-02 cells","volume":"37","author":"Zhan","year":"2019","journal-title":"J. Shanghai Jiaot."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1516217\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T06:23:57Z","timestamp":1734589437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1516217\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":22,"alternative-id":["10.3389\/fphar.2024.1516217"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1516217","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"article-number":"1516217"}}